The pharmaceutical industry is under increased pressure to advance development of new therapies in a fast and efficient manner, whilst ensuring safety and quality of data.
A critical segment of the drug development process is the PROOF OF CONCEPT phase, namely the „first-in-patient“ (Phase IB or IIA) clinical trials which aim to detect the first efficacy signal of new therapies in the given targeted patient population/disease.
The data resulting out of the PROOF-OF-CONCEPT trials are the foundation for deciding on whether to stop or to continue the research of new therapeutic options before making any large investments to advance the drugs to later phases of development.
An increasing number of clinical trials need expert research facilities able to manage sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in patient populations. Their protocols imply complex medical assessments, intensive PK/PD procedures and require a strong infrastructure for hospitalization.
The typical clinical trial sites are lacking dedicated personnel, and this personnel often lacks expertise to execute such complex research. As a consequence, to perform PROOF OF CONCEPT clinical trials (which require relatively low numbers of patients, ranging 12 to 200), pharmaceutical companies must involve a multitude of clinical trial sites to compensate these shortcomings. High costs, delays and quality issues ensue.
At ARENSIA, we understood industry needs, and to meet them, we have built over the last decade our proprietary network of research clinics in 8 countries, serving numerous therapeutic areas.
All ARENSIA Clinics are entirely dedicated to speeding up PROOF OF CONCEPT trials, and have all systems in place to ensure highest safety standards for patients, as well as quality of data.
Typical clinical trial sites are overcrowded by daily hospital duties, lack of staff (especially research-oriented personnel), competition for same populations and long timelines for contract negotiations. ARENSIA Clinics achieve a remarcable time reduction through unrivalled recruiting performance! The shortened time and the different setup of concentrating effort on few ARENSIA Clinics (instead of the traditional high number of sites) lead to an overall budget reduction of at least 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial.
93% repeat business proves that ARENSIA’s value proposition is the long expected disruptive break-through in time and cost! This has allowed our continuous growth, while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, as well as global CROs.
In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.
We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.
We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.
ARENSIA is delighted to introduce its latest face-to-face summit platform: INNOVATIONXCHANGE! On November 6th, we will inaugurate our first event a...
READ MORENeuroscience clinical trials thrive on a diverse range of factors such as novel target identification methods, comprehensive AI integration, real-worl...
READ MOREARENSIA Clinic in Tbilisi has expanded its facilities to 800 sqm and its staff to 50 FTEs, with more medics and more nurses - proof of our commitment ...
READ MOREFantastic event and vivid discussions at yesterday’s “Clinical Trials in Ukraine” conference. We are thankful to the host, The Minis...
READ MOREFollowing a successful day at Ukraine’s Recovery Conference in London, a delightful evening at the reception at Lancaster House! Our CEO, D...
READ MOREARENSIA stands with Ukraine! - from day one of the Russian invasion back in February 2022. Not with words, but with deeds! We are proud that the pheno...
READ MOREARENSIA is thrilled to exhibit in person at the “Clinical Trials in Ukraine” conference, taking place in Kyiv on Thursday, June 29.&n...
READ MORE